These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 15929079)

  • 1. c-MYC Asn11Ser is associated with increased risk for familial breast cancer.
    Wirtenberger M; Hemminki K; Försti A; Klaes R; Schmutzler RK; Grzybowska E; Bermejo JL; Wappenschmidt B; Bugert P; Butkiewicz D; Pamula J; Pekala W; Zientek H; Bartram CR; Burwinkel B
    Int J Cancer; 2005 Nov; 117(4):638-42. PubMed ID: 15929079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
    Adem C; Soderberg CL; Hafner K; Reynolds C; Slezak JM; Sinclair CS; Sellers TA; Schaid DJ; Couch F; Hartmann LC; Jenkins RB
    Genes Chromosomes Cancer; 2004 Sep; 41(1):1-11. PubMed ID: 15236312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
    Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
    Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.
    Sigurdson AJ; Hauptmann M; Chatterjee N; Alexander BH; Doody MM; Rutter JL; Struewing JP
    BMC Cancer; 2004 Mar; 4():9. PubMed ID: 15113441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N and C-terminal sub-regions in the c-Myc transactivation region and their joint role in creating versatility in folding and binding.
    Fladvad M; Zhou K; Moshref A; Pursglove S; Säfsten P; Sunnerhagen M
    J Mol Biol; 2005 Feb; 346(1):175-89. PubMed ID: 15663936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis.
    Figueiredo JC; Knight JA; Cho S; Savas S; Onay UV; Briollais L; Goodwin PJ; McLaughlin JR; Andrulis IL; Ozcelik H
    BMC Cancer; 2007 Jun; 7():99. PubMed ID: 17567920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.
    Balleine RL; Provan PJ; Pupo GM; Pathmanathan N; Cummings M; Farshid G; Salisbury EL; Bilous AM; Byth K; ; Mann GJ
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1082-94. PubMed ID: 20815029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.
    Frank B; Hemminki K; Wirtenberger M; Bermejo JL; Bugert P; Klaes R; Schmutzler RK; Wappenschmidt B; Bartram CR; Burwinkel B
    Carcinogenesis; 2005 Mar; 26(3):643-7. PubMed ID: 15550452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
    Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
    Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
    Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
    Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and properties of a Myc derivative that efficiently homodimerizes.
    Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
    Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients.
    Pastrello C; Polesel J; Della Puppa L; Viel A; Maestro R
    Carcinogenesis; 2010 Dec; 31(12):2124-6. PubMed ID: 20810544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAD51 135G>C polymorphism and risk of familial breast cancer in a South American population.
    Jara L; Acevedo ML; Blanco R; Castro VG; Bravo T; Gómez F; Waugh E; Peralta O; Cabrera E; Reyes JM; Ampuero S; González-Hormazábal P
    Cancer Genet Cytogenet; 2007 Oct; 178(1):65-9. PubMed ID: 17889711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer.
    Takatsuno Y; Mimori K; Yamamoto K; Sato T; Niida A; Inoue H; Imoto S; Kawano S; Yamaguchi R; Toh H; Iinuma H; Ishimaru S; Ishii H; Suzuki S; Tokudome S; Watanabe M; Tanaka J; Kudo SE; Mochizuki H; Kusunoki M; Yamada K; Shimada Y; Moriya Y; Miyano S; Sugihara K; Mori M
    Ann Surg Oncol; 2013 Apr; 20(4):1395-402. PubMed ID: 22976378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk.
    Yang R; Schlehe B; Hemminki K; Sutter C; Bugert P; Wappenschmidt B; Volkmann J; Varon R; Weber BH; Niederacher D; Arnold N; Meindl A; Bartram CR; Schmutzler RK; Burwinkel B
    Breast Cancer Res Treat; 2010 Jun; 121(3):693-702. PubMed ID: 19921425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?
    Jakubowska A; Jaworska K; Cybulski C; Janicka A; Szymańska-Pasternak J; Lener M; Narod SA; Lubiński J;
    Eur J Cancer; 2009 Mar; 45(5):837-42. PubMed ID: 19071013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families.
    Bonache S; Gutierrez-Enriquez S; Tenés A; Masas M; Balmaña J; Diez O
    Gynecol Oncol; 2013 Nov; 131(2):460-3. PubMed ID: 23911796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease family history and modification of breast cancer risk in common BRCA2 variants.
    Seymour IJ; Casadei S; Zampiga V; Rosato S; Danesi R; Falcini F; Strada M; Morini N; Naldoni C; Paradiso A; Tommasi S; Schittulli F; Amadori D; Calistri D
    Oncol Rep; 2008 Mar; 19(3):783-6. PubMed ID: 18288416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.